Jemincare Group Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jemincare Group Co., Ltd
An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
- Large Molecule
- Other Names / Subsidiaries
- Shanghai Jemincare Pharmaceutical Co., Ltd.